12 Month Price Forecast For BRKR
Distance to BRKR Price Forecasts
BRKR Price Momentum
๐ค Considering Bruker (BRKR)?
Join 5,000+ investors getting our exclusive market analysis every Monday & Thursday. Stay ahead of breakout opportunities.
Disclaimer: The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Data last updated: February 6, 2025 12:08 PM UTC
BRKR Analyst Ratings & Price Targets
Based on our analysis of 18 Wall Street analysts, BRKR has a consensus that is bullish. The median price target is $72.41, with forecasts ranging from $60.00 to $85.00. Currently, there are 10 Buy ratings, 5 Hold ratings, and 0 Sell ratings.
With BRKR currently trading at $57.43, the median price forecast suggests a 26.1% upside. The most optimistic forecast comes from Puneet Souda at SVB Leerink, projecting a 48.0% upside, while Matthew Sykes at Goldman Sachs provides the most conservative target, suggesting a 4.5% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
BRKR Analyst Consensus
BRKR Price Target Range
Latest BRKR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for BRKR.
Date | Firm | Analyst | Rating | Change | Price Target |
---|---|---|---|---|---|
Jan 17, 2025 | Guggenheim | Subbu Nambi | Buy | Reiterates | $0.00 |
Dec 19, 2024 | Guggenheim | Subbu Nambi | Buy | Initiates | $72.00 |
Dec 13, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $80.00 |
Dec 10, 2024 | UBS | Dan Leonard | Neutral | Assumes | $66.00 |
Dec 5, 2024 | Goldman Sachs | Matthew Sykes | Neutral | Upgrade | $60.00 |
Nov 6, 2024 | TD Cowen | Dan Brennan | Hold | Maintains | $70.00 |
Nov 6, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $75.00 |
Nov 6, 2024 | Barclays | Terence Malone | Overweight | Maintains | $69.00 |
Nov 6, 2024 | Wells Fargo | Brandon Couillard | Overweight | Maintains | $75.00 |
Oct 15, 2024 | Barclays | Terence Malone | Overweight | Initiates | $75.00 |
Sep 30, 2024 | Wolfe Research | Doug Schenkel | Peer Perform | Downgrade | $0.00 |
Aug 27, 2024 | Wells Fargo | Brandon Couillard | Overweight | Initiates | $78.00 |
Aug 7, 2024 | TD Cowen | Max Masucci | Hold | Maintains | $72.00 |
Jul 11, 2024 | Citigroup | Buy | Maintains | $0.00 | |
Jul 10, 2024 | Citigroup | Patrick Donnelly | Buy | Maintains | $80.00 |
Jul 9, 2024 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $60.00 |
May 20, 2024 | Stifel | Daniel Arias | Hold | Maintains | $77.00 |
May 20, 2024 | B of A Securities | Derik De Bruin | Buy | Maintains | $90.00 |
Apr 10, 2024 | Goldman Sachs | Matthew Sykes | Sell | Maintains | $74.00 |
Mar 1, 2024 | UBS | John Sourbeer | Buy | Maintains | $102.00 |
Stocks Similar to Bruker Corp
The following stocks are similar to Bruker based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Bruker Corp (BRKR) Financial Data
Bruker Corp has a market capitalization of $8.71B with a P/E ratio of 27.7x. The company generates $3.24B in trailing twelve-month revenue with a 9.4% profit margin.
Revenue growth is +16.4% quarter-over-quarter, while maintaining an operating margin of +10.0% and return on equity of +19.7%.
Valuation Metrics
Growth & Margins
Financial Health
๐ฅ Want More High-Potential Stock Ideas?
Join 5,000+ investors getting our research on stocks with massive upside potential.

Bruker Corp (BRKR) Company Overview
About Bruker Corp
Develops scientific instruments and analytical solutions.
The company generates revenue by developing, manufacturing, and distributing a wide range of scientific instruments and diagnostic solutions across various segments including life sciences, analytical tools, and superconducting technologies. It serves diverse markets including healthcare, research, and industrial applications, with products that address specific needs like pathogen identification and molecular diagnostics.
Bruker Corporation operates through four main segments and offers a variety of specialized tools and systems, including mass spectrometry and portable analytical instruments. The company was established in 1991 and is based in Billerica, Massachusetts, positioning itself as a key player in the scientific instruments market with a strong international presence.
Company Information
Sector
Healthcare
Industry
Medical Devices
Employees
9,707
CEO
Dr. Frank H. Laukien Ph.D.
Country
United States
IPO Year
2000
Website
www.bruker.comBruker Corp (BRKR) Latest News & Analysis
BRKR's NANO Life Science fluorescence microscopy is benefitting from increased product innovation and growing demand for research applications.
BRKR's growth in fluorescence microscopy indicates strong market demand and innovation, potentially leading to increased revenue and competitive advantage, impacting stock performance positively.
Bruker Corporation (NASDAQ: BRKR) is currently undervalued at under $74, with growth potential from strategic acquisitions in high-growth markets, despite weaker EPS and margins.
Bruker Corporation's undervaluation and strategic acquisitions position it for significant growth in high-demand markets, potentially enhancing profitability and appealing to investors seeking upside.
Bruker has launched the LUMOS II ILIM QCL-based IR microscope, targeting the pharmaceutical and life sciences research sectors.
Bruker's launch of the LUMOS II ILIM QCL-based IR microscope enhances its product offerings, potentially driving revenue growth in the pharma and life sciences sectors, impacting stock performance.
Bruker Corporation (Nasdaq: BRKR) launched the LUMOSโข II ILIM, a new infrared imaging microscope enhancing imaging speed and resolution for pharma and life science research.
Bruker's launch of the LUMOS II ILIM could boost revenue from pharma and life sciences, enhancing market position and driving stock performance, appealing to growth-focused investors.
Bruker Corporation (Nasdaq: BRKR) will present at the J.P. Morgan Healthcare Conference on January 13, 2025, at 3:45 PM PST, featuring key executives. A live audio webcast will be available.
Bruker's participation in a major healthcare conference signals potential growth opportunities and strategic initiatives, influencing investor sentiment and stock performance.
Bruker Corporation announced that a U.S. District Court upheld a jury's damages award in a patent infringement case involving its NanoString business and 10x Genomics.
The court's ruling on damages for Bruker's NanoString products affects financial outlook and potential liabilities, impacting stock performance and investor confidence.
Frequently Asked Questions About BRKR Stock
What is Bruker Corp's (BRKR) stock forecast for 2025?
Based on our analysis of 18 Wall Street analysts, Bruker Corp (BRKR) has a median price target of $72.41. The highest price target is $85.00 and the lowest is $60.00.
Is BRKR stock a good investment in 2025?
According to current analyst ratings, BRKR has 10 Buy ratings, 5 Hold ratings, and 0 Sell ratings. The stock is currently trading at $57.43. Always conduct your own research and consider your investment goals before making investment decisions.
What is the price prediction for BRKR stock?
Wall Street analysts predict BRKR stock could reach $72.41 in the next 12 months. This represents a 26.1% increase from the current price of $57.43. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Bruker Corp's business model?
The company generates revenue by developing, manufacturing, and distributing a wide range of scientific instruments and diagnostic solutions across various segments including life sciences, analytical tools, and superconducting technologies. It serves diverse markets including healthcare, research, and industrial applications, with products that address specific needs like pathogen identification and molecular diagnostics.
What is the highest forecasted price for BRKR Bruker Corp?
The highest price target for BRKR is $85.00 from Puneet Souda at SVB Leerink, which represents a 48.0% increase from the current price of $57.43.
What is the lowest forecasted price for BRKR Bruker Corp?
The lowest price target for BRKR is $60.00 from Matthew Sykes at Goldman Sachs, which represents a 4.5% increase from the current price of $57.43.
What is the overall BRKR consensus from analysts for Bruker Corp?
The overall analyst consensus for BRKR is bullish. Out of 18 Wall Street analysts, 10 rate it as Buy, 5 as Hold, and 0 as Sell, with a median price target of $72.41.
How accurate are BRKR stock price projections?
Stock price projections, including those for Bruker Corp, are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.